Skip to Content

Prospector Capital Appreciation PCAFX

Medalist Rating as of | See Prospector Investment Hub
  • NAV / 1-Day Return 22.79  /  +0.97 %
  • Total Assets 41.7 Mil
  • Adj. Expense Ratio
    1.260%
  • Expense Ratio 1.260%
  • Distribution Fee Level High
  • Share Class Type No Load
  • Category Moderately Aggressive Allocation
  • Investment Style Mid Blend
  • Credit Quality / Interest Rate Sensitivity
  • Status Open
  • TTM Yield 0.49%
  • Turnover 41%

USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:17 PM GMT+0

Morningstar’s Analysis PCAFX

Will PCAFX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A drop in People Pillar rating is the primary driver of Prospector Capital Appreciation's downgrade to a Morningstar Medalist Rating of Neutral from Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PCAFX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 27.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

First American Treasury Obligs X

5.65 2.2 Mil
Cash and Equivalents

Eaton Corp PLC

4.07 1.6 Mil
Industrials

Leidos Holdings Inc

3.17 1.2 Mil
Technology

Halozyme Therapeutics Inc 1%

2.68 1.0 Mil
Corporate

Fairfax Financial Holdings Ltd Shs Subord.Vtg

2.62 1.0 Mil
Financial Services

Merck & Co Inc

2.62 1.0 Mil
Healthcare

Curtiss-Wright Corp

2.50 976,883
Industrials

Brown & Brown Inc

2.50 975,463
Financial Services

Hess Corp

2.43 948,111
Energy

Abbott Laboratories

2.36 923,240
Healthcare